The Maine Medical Center BioBank (MMC BB) provides human biospecimens with annotated clinical data to the research community to aid in the characterization of disease with the goal of improved patient therapies and the advancement of science and personalized medicine.
Excess surgical tissue and other biospecimens that would otherwise be discarded is de-identified, processed, stored and distributed to research scientists at MMC, MMCRI, other academic institutes, pharmaceutical and biotech companies and commercial specimen repositories.
The BioBank is partnered withTufts Medical Center’s Biorepository, more information about which can be found on their website.
BioBank Overview Video
More than 50,000 samples with annotated data collected primarily from cancer and inflammatory disease surgeries, are available to investigators in fresh, frozen or FFPE (formalin fixed-paraffin embedded) sample formats.
Tissue microarrays, constructed by the MMCRI Histopathology Core are also available upon request. Sample inventory and tracking is managed by Progeny software.
The MMC BB is accredited by the College of American Pathologists (CAP) and its operations are guided by NCI Best Practices for Biorepositories and by the International Society of Biological and Environmental Repositories (IBSER).
The TCGA has compiled a database of genomic alterations associated with at least 20 different types of cancer to date. The MMC BioBank has provided tissue from prostate and sarcoma tumors with annotated clinical data to support the TCGA program.
Over 300 patient-derived xenograft (PDX) tumors are available for engrafting into immunocompromised NSG™ mice for shipment to your facility or use in JAX-directed preclinical efficacy studies.
Lung Stem Cell Study: Cloning and Characterization of Adult Lung Stem Cells for Understanding Airway Diseases
Ovarian and Follicular Cancer Study: Cloning and Characterization of Adult Ovarian and Fallopian Tube Stem Cells for Understanding the Etiology of Ovarian Cancer
Esophageal Stem Cell Study: Cloning and Characterization of Barrett’s Esophagus Stem Cells for Risk Assessment and Targeted Therapy Development.
The Maine Triple Negative Breast Cancer Study: Cloning and Characterization of stem cells from the tumors of triple negative (ER, PR and HER-2/neu) breast cancer patients for development of improved therapies